Adding PET/CT scans to follow-up care after treatment of non-small cell lung cancer
Tests added PET/CT scans during follow-up of people with non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
Key facts
- Where
- Amsterdam, Apeldoorn & Zutphen, Breda, Deventer, Ede, Eindhoven & Veldhoven, Emmen, Enschede, Gouda, Groningen, Heerenveen, Hilversum, Hoorn, Nijmegen, Roosendaal, Rotterdam, Schiedam, The Hague, Tilburg, Utrecht, Utrecht & Nieuwegein, and Winterswijk, NetherlandsSee the 27 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer who were treated to remove all of the disease and have started follow-up care. It compares follow-up with extra PET/CT scans to follow-up with usual CT scans.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Stage III non-small cell lung cancer, proven by cell or tissue tests before treatment started
- Earlier treatment
- Must have had treatment meant to remove all of the disease and have started follow-up care. Extra treatment after surgery is allowed during follow-up.
Main reasons for not taking part
- Life expectancy shorter than 6 months at the end of treatment
- Signs that the cancer came back before randomization (4 months of follow-up)
- Performance status worse than ECOG 0-2
- Any condition that would interfere with the study results, in the investigator's opinion
Read by machine on 12 November 2026.
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsContact: M. SminkTaking people
- Antoni Van Leeuwenhoek (Nederlands Kanker Instituut)Amsterdam, NetherlandsContact: E. SchoutenTaking people
- OLVGAmsterdam, NetherlandsContact: Research LonggeneeskundeTaking people
- Gelre ZiekenhuizenApeldoorn & Zutphen, NetherlandsContact: M. van NistelrooijTaking people
- Amphia ZiekenhuisBreda, NetherlandsContact: Research LongoncologieTaking people
- Deventer ZiekenhuisDeventer, NetherlandsContact: Research OncologieTaking people
- Ziekenhuis Gelderse ValleiEde, NetherlandsContact: A. MuldersTaking people
- Máxima Medisch CentrumEindhoven & Veldhoven, NetherlandsContact: M. BaxTaking people
- TreantEmmen, NetherlandsContact: T. BokhorstTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsContact: Onderzoeksbureau LonggeneeskundeTaking people
- Groene Hart ZiekenhuisGouda, NetherlandsContact: K. van ElstTaking people
- Martini ZiekenhuisGroningen, NetherlandsContact: I. JonkerTaking people
- Tjongerschans ziekenhuisHeerenveen, NetherlandsContact: H. Langenberg-PostTaking people
- Tergooi MCHilversum, NetherlandsContact: L. KwastTaking people
- Dijklander ZiekenhuisHoorn, NetherlandsContact: Y. van DekkenTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsContact: Research LongTaking people
- RadboudumcNijmegen, NetherlandsContact: Nicole E. Billingy, MSc.Taking people
- Bravis ZiekenhuisRoosendaal, NetherlandsContact: J. SchellekensTaking people
- Maasstad ZiekenhuisRotterdam, NetherlandsContact: Research OncologieTaking people
- Franciscus Gasthuis & VlietlandSchiedam, NetherlandsContact: S. BroerseTaking people
- Haaglanden Medisch CentrumThe Hague, NetherlandsContact: E. GortmakerTaking people
- HagaZiekenhuisThe Hague, NetherlandsContact: Research LongziektenTaking people
- Elisabeth-Tweesteden ZiekenhuisTilburg, NetherlandsContact: A. VelthovenTaking people
- DiakonessenhuisUtrecht, NetherlandsContact: Research OncologieTaking people
- UMC UtrechtUtrecht, NetherlandsContact: S. JansTaking people
- St. Antonius ZiekenhuisUtrecht & Nieuwegein, NetherlandsContact: R&D LongoncologieTaking people
- Streekziekenhuis Koningin BeatrixWinterswijk, NetherlandsContact: E. Klein ZeggelinkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Radboud University Medical Center
- Trial code
- NCT06082492
- Record updated
- 5 February 2025
- Original description
The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance.Read full original descriptionShow less
The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study
The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance.
Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group.
Other tasks include:
* filling in quality of life (QOL) questionnaires at every time point; * participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional); * collecting blood at the follow-up time points for our secondary endpoint (optional).
Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.
Inclusion: To be eligible to participate in this study, a subject must meet all of the following criteria at the timing of randomization:; Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment; Treated with curative intent and started follow-up care; All adjuvant treatments are permitted as co-intervention during follow-up care; Age 18 years or older; ECOG Performance Status classification 0-2 at moment of inclusion; Written and signed informed consent by the patient or patient's representative (with the understanding that consent may be withdrawn by the patient or patient's representative at any time without consequences to future medical care).
Exclusion: Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results; A potential subject who meets any of the following criteria will be excluded from participation in this study:; Life expectancy shorter than 6 months at the end of curative intent treatment; Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up).
Eligible for this study are patients with stage III NSCLC (8th edition TNM Classification) who (are about to) start(ed) follow-up care (which may include adjuvant treatment) at a participating hospital. Patients may already be included during their curative intent treatment. Patients enter a screening period that runs until their randomization.